Forest strives to positively impact the health and quality of life of patients through the development of innovative prescription drug therapies.
06.19.2009 - Forest Laboratories Announces Positive Top-line Data from Two Pivotal Phase III Trials of Ceftaroline for the Treatment of Community-acquired Bacterial Pneumonia (CABP) Requiring Hospitalization
05.31.2009 - Ironwood and Forest Present Additional Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation
05.12.2009 - Ironwood and Forest to Present Additional Phase 2b Data for Novel Gastrointestinal Agent Linaclotide